Aripiprazole: a treatment for severe coprolalia in "refractory" Gilles de la Tourette syndrome.
Identifieur interne : 002408 ( PubMed/Corpus ); précédent : 002407; suivant : 002409Aripiprazole: a treatment for severe coprolalia in "refractory" Gilles de la Tourette syndrome.
Auteurs : Mouna Ben Djebara ; Yulia Worbe ; Michael Schüpbach ; Andreas HartmannSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2008.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antipsychotic Agents, Piperazines, Quinolones.
- drug therapy : Tourette Syndrome.
- Adult, Humans, Male, Treatment Outcome.
Abstract
Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28-year-old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics.
DOI: 10.1002/mds.21859
PubMed: 18067182
Links to Exploration step
pubmed:18067182Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Aripiprazole: a treatment for severe coprolalia in "refractory" Gilles de la Tourette syndrome.</title>
<author><name sortKey="Ben Djebara, Mouna" sort="Ben Djebara, Mouna" uniqKey="Ben Djebara M" first="Mouna" last="Ben Djebara">Mouna Ben Djebara</name>
<affiliation><nlm:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Worbe, Yulia" sort="Worbe, Yulia" uniqKey="Worbe Y" first="Yulia" last="Worbe">Yulia Worbe</name>
</author>
<author><name sortKey="Schupbach, Michael" sort="Schupbach, Michael" uniqKey="Schupbach M" first="Michael" last="Schüpbach">Michael Schüpbach</name>
</author>
<author><name sortKey="Hartmann, Andreas" sort="Hartmann, Andreas" uniqKey="Hartmann A" first="Andreas" last="Hartmann">Andreas Hartmann</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="doi">10.1002/mds.21859</idno>
<idno type="RBID">pubmed:18067182</idno>
<idno type="pmid">18067182</idno>
<idno type="wicri:Area/PubMed/Corpus">002408</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Aripiprazole: a treatment for severe coprolalia in "refractory" Gilles de la Tourette syndrome.</title>
<author><name sortKey="Ben Djebara, Mouna" sort="Ben Djebara, Mouna" uniqKey="Ben Djebara M" first="Mouna" last="Ben Djebara">Mouna Ben Djebara</name>
<affiliation><nlm:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Worbe, Yulia" sort="Worbe, Yulia" uniqKey="Worbe Y" first="Yulia" last="Worbe">Yulia Worbe</name>
</author>
<author><name sortKey="Schupbach, Michael" sort="Schupbach, Michael" uniqKey="Schupbach M" first="Michael" last="Schüpbach">Michael Schüpbach</name>
</author>
<author><name sortKey="Hartmann, Andreas" sort="Hartmann, Andreas" uniqKey="Hartmann A" first="Andreas" last="Hartmann">Andreas Hartmann</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Humans</term>
<term>Male</term>
<term>Piperazines (therapeutic use)</term>
<term>Quinolones (therapeutic use)</term>
<term>Tourette Syndrome (drug therapy)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Piperazines</term>
<term>Quinolones</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Tourette Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Humans</term>
<term>Male</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28-year-old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">18067182</PMID>
<DateCreated><Year>2008</Year>
<Month>03</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted><Year>2008</Year>
<Month>05</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>05</Month>
<Day>27</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>23</Volume>
<Issue>3</Issue>
<PubDate><Year>2008</Year>
<Month>Feb</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Aripiprazole: a treatment for severe coprolalia in "refractory" Gilles de la Tourette syndrome.</ArticleTitle>
<Pagination><MedlinePgn>438-40</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28-year-old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics.</AbstractText>
<CopyrightInformation>2007 Movement Disorder Society</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ben Djebara</LastName>
<ForeName>Mouna</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Centre d'Investigation Clinique, Fédération de Neurologie, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Worbe</LastName>
<ForeName>Yulia</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Schüpbach</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hartmann</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015363">Quinolones</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>82VFR53I78</RegistryNumber>
<NameOfSubstance UI="C094645">aripiprazole</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010879">Piperazines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D015363">Quinolones</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005879">Tourette Syndrome</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year>
<Month>12</Month>
<Day>11</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2008</Year>
<Month>5</Month>
<Day>9</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2007</Year>
<Month>12</Month>
<Day>11</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.21859</ArticleId>
<ArticleId IdType="pubmed">18067182</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002408 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002408 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:18067182 |texte= Aripiprazole: a treatment for severe coprolalia in "refractory" Gilles de la Tourette syndrome. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:18067182" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |